Abeona Therapeutics
ABEO
108 hedge funds and large institutions have $177M invested in Abeona Therapeutics in 2026 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 40 increasing their positions, 33 reducing their positions, and 11 closing their positions.
100% more call options, than puts
Call options by funds: $8.91M | Put options by funds: $4.45M
55% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 11
21% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 33
4% more funds holding
Funds holding: 104 → 108 (+4)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
2.55% less ownership
Funds ownership: 71.85% → 69.3% (-2.5%)
14% less capital invested
Capital invested by funds: $205M → $177M (-$28.1M)
Top Buyers
Top Sellers
ABEO Hedge Fund Activity: Q1 2026 in Review
108 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Abeona Therapeutics (ABEO) for Q1 2026, worth a combined $177M — down 14% from $205M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new ABEO positions and 11 closed out — a net gain of 6 holders — while 40 added to existing stakes and 33 trimmed.
The largest buyer was AIGH Capital Management, adding an estimated $5.5M. The largest seller was Vivo Capital, exiting entirely with an estimated $9.71M sold.
- 108 institutional investors held Abeona Therapeutics (ABEO) as of Q1 2026, up from 104 in Q4 2025.
- Funds reported $177M of Abeona Therapeutics stock for Q1 2026, down 14% quarter-over-quarter.
- 17 funds opened new Abeona Therapeutics positions in Q1 2026 and 11 closed out, a net change of +6 holders.
- The largest Abeona Therapeutics buyer in Q1 2026 was AIGH Capital Management, an estimated $5.5M added.
- The largest Abeona Therapeutics seller in Q1 2026 was Vivo Capital, an estimated $9.71M sold.
Based on aggregated 13F filings for Q1 2026.